Extracorporeal shock wave lithotripsy is safe and effective for pediatric patients with chronic pancreatitis

Authors
Dan Wang1, Ya-Wei Bi1, Jun-Tao Ji2, Lei Xin1, Jun Pan1, Zhan Liao1, Ting-Ting Du1, Jin-Huan Lin1, Di Zhang1, Xiang-Peng Zeng1, Bo Ye3, Wen-Bin Zou1, Hui Chen2, Ting Xie4, Bai-Rong Li5, Zhao-Hong Zheng6, Zhao-Shen Li1, Liang-Hao Hu1,2

Institutions
1 Department of Gastroenterology, Changhai Hospital, The Second Military Medical University, Shanghai, China
2 Digestive Endoscopy Center, Changhai Hospital, The Second Military Medical University, Shanghai, China
3 Department of Surgery, Jinling Hospital, Nanjing, China
4 Department of Gastroenterology, Zhongda Hospital, Southeast University, Nanjing, China
5 Department of Gastroenterology, Air Force General Hospital, Beijing, China
6 Department of Traditional Chinese Medicine, Jiangdu Hospital, Yangzhou, China

submitted 23.9.2016
accepted after revision 6.2.2017

Bibliography
DOI http://dx.doi.org/10.1055/s-0043-104527
Published online: 12.4.2017 | Endoscopy 2017; 49: 447–455
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0013-726X

Corresponding author
Liang-Hao Hu, MD or Zhao-Shen Li, MD, Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai 200433, China
Fax: +86-21-55621735
lianghao-hu@hotmail.com
zhao-shen-li@hotmail.com

ABSTRACT
Background and aims Pancreatic extracorporeal shock wave lithotripsy (P-ESWL) is recommended as the first-line treatment for pancreatic stones. However, how well P-ESWL performs in pediatric patients remains unclear. We aimed to evaluate the safety and efficacy of P-ESWL for pediatric patients with chronic pancreatitis.

Methods This prospective observational study was conducted in patients with painful chronic pancreatitis who underwent P-ESWL. Patients aged under 18 years were included in the pediatric group; patients aged over 18 years who underwent P-ESWL in the same period were assigned to the control group. For investigation of long-term follow-up, the pediatric group were matched with patients from the control group in a 1:1 ratio. The primary outcomes were P-ESWL complications and pain relief. The secondary outcomes included: stone clearance, physical and mental health, quality of life score, and growth and developmental state.

Results From March 2011 to March 2015, P-ESWL was performed in 1135 patients (72 in the pediatric group, 1063 in the control group). No significant differences were observed in the occurrence of P-ESWL complications between the two groups (11.1% vs. 12.8%; \( P = 0.68 \)). Among the 67 pediatric patients (93.1%) who underwent follow-up for 3.0 years (range 1.3–5.2), complete pain relief was achieved in 52 patients (52/67; 77.6%); this value was not significantly different from that of the matched controls (55/69; 79.7%; \( P = 0.94 \)).

Conclusions P-ESWL is safe and effective for pediatric patients with chronic pancreatitis. It can promote significant pain relief and stone clearance, and can benefit growth and development.

Introduction
Chronic pancreatitis is characterized by pancreatic inflammation and fibrosis, which eventually leads to the destruction of the pancreatic parenchyma and loss of both exocrine and endocrine function.

Recent studies have estimated that the incidence of chronic pancreatitis in children is approximately 0.5 per 100 000 per year [1–3]. Despite this modest incidence rate, the disease burden of chronic pancreatitis in pediatric patients is substantial owing to the extreme disruption caused to the patients’ childhood and education. Children with chronic pancreatitis typically suffer from chronic or severe relapsing abdominal pain, with frequent emergency department visits, hospitalizations, and...
school absences [4]. Moreover, malnutrition caused by decreased dietary intake and malabsorption is known to retard the growth and development of these children [5]. Pain control is the mainstay of chronic pancreatitis management. Characteristic pathological changes, such as pancreatic duct strictures and stones, lead to intraductal hypertension, which is the most important factor for abdominal pain. Pancreatic stones are present in 50% of patients with chronic pancreatitis and 12%–69.7% of pediatric patients with chronic pancreatitis [4,6–9]. Treatment of pancreatic stones in adults is standardized, with guidelines available; surgery and endoscopy represent the first-line therapies [10]. However, a consensus regarding the treatment strategy for pediatric patients with chronic pancreatitis is not available [11]. According to previous studies, for pediatric chronic pancreatitis coexisting with pancreatic stones, surgery and endoscopy are also considered safe and effective therapies [12–15]. Because of the irreversibility of the disease, children with pancreatic stones have a higher risk of recurrence over a longer period of time than adults, therefore indicating a higher cumulative likelihood of stone recurrence throughout their lives.

Pancreatic extracorporeal shock wave lithotripsy (P-ESWL) is minimally invasive, effective, and safe for the management of adults with pancreatic stones and does not impede subsequent endoscopy or surgery in patients with recurrent stones in the future. However, the safety and efficacy of P-ESWL in pediatric patients has not been previously reported.

The main concern with regard to the application of P-ESWL in pediatric patients is the potential for complications of the procedure, such as acute pancreatitis, perforation, bleeding, infection, and anesthesia-related side effects. The aim of our study was to evaluate the safety and efficacy of P-ESWL in the treatment of pediatric patients with pancreatic stones.

Patients and methods

Study design

We performed a prospective cohort study to evaluate the outcome of pediatric patients with pancreatic stones who underwent P-ESWL in comparison to the outcome of all adult patients who underwent P-ESWL within the same period. Written informed consent was obtained from each patient, and the study was approved by the Ethics Committee of Changhai Hospital. Informed consent for patients aged less than 18 years was provided by their guardian.

Patients and data collection

The target population for P-ESWL was patients with painful chronic pancreatitis and radiopaque stones of ≥5 mm. Patients with a suspected or established malignant mass or pancreatic ascites, and pregnant patients were not considered for the P-ESWL treatment. The diagnosis of chronic pancreatitis was established primarily based on computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic ultrasound (EUS) examinations according to the Asia-Pacific consensus [16]. All of the patients were evaluated with CT scans prior to P-ESWL. Patients aged less than 18 years who underwent P-ESWL treatment from March 2011 to March 2015 were included in the pediatric group, whereas patients older than 18 years who underwent P-ESWL treatment in the same period were assigned to the control group. Demographic data and the disease course of the chronic pancreatitis, including the onset, manifestations, diagnosis, and previous treatments, were recorded in detail upon admission to the hospital. In addition, the visual analog scale (VAS) pain score, quality of life score, and Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) questionnaire were completed.

To evaluate the long-term outcomes of P-ESWL in pediatric patients, we matched the pediatric group with patients from the control group in a 1:1 ratio. The matching principles were sex, type of abdominal pain, and location of the stone(s).

For patients in the pediatric group and patients selected as the matched controls, revisits were required annually after P-ESWL therapy. During the revisits, contrast-enhanced CT of the pancreas was performed, and follow-up data, including the disease course of the chronic pancreatitis after P-ESWL, VAS pain score, usage of medication, disease-related inability to work, quality of life score, and SF-36 questionnaire, were recorded. In June 2016, we evaluated the patients in the pediatric group and the matched controls included in this study.

Treatment strategy

In this study, all of the patients involved were treated with P-ESWL after admission to the hospital. P-ESWL was performed using a third-generation electromagnetic lithotripter (Compact Delta II; Dornier Med Tech, Wessling, Germany). After they had received intravenous sedation analgesia (flurbiprofen combined with remifentanil), the patients were treated in the supine position with the shock head touching the abdomen from above. Pancreatic duct stones were targeted by the lithotripter using fluoroscopy.

For each individual patient, the P-ESWL session was repeated on consecutive days until the stone was fragmented to ≤3 mm in diameter. No more than 5000 shocks at an intensity of 6 (16 000 kV) on a scale of 1–6, at a frequency of 120 shocks/min were delivered during each therapeutic session. The duration of each session was 60–90 minutes [17,18]. Radiation protection was provided by adhering to the European Society of Gastrointestinal Endoscopy (ESGE) guidelines [19]. For patients in the pediatric group, a pancreatic surgery team was on call during the study in case of severe complications.

Endoscopic retrograde cholangiopancreatography (ERCP) was routinely performed 48 hours after the last P-ESWL (►Video 1, ►Fig.1). The treatment principle for the ERCP mainly followed the ESGE guidelines [11].

Outcome measures

A standardized evaluation of symptoms and investigations was carefully performed after every P-ESWL session and after the ERCP that was performed post-ESWL. Any complications and relevant treatments were documented during the subsequent 30 days after P-ESWL and ERCP.
The primary outcomes were complications of P-ESWL [17] and pain relief. Secondary outcomes were: stone clearance, growth and development, physical and mental health, quality of life score, and changes in exocrine and endocrine pancreatic function.

The primary outcomes were complications of P-ESWL [17] and pain relief. Secondary outcomes were: stone clearance, growth and development, physical and mental health, quality of life score, and changes in exocrine and endocrine pancreatic function.

Pain relief at the end of the follow-up period was classified as complete relief (Izbicki pain score ≤ 10) or partial relief (Izbicki pain score > 10 after a decrease of >50%) [20, 21]. Stone clearance was evaluated at the ERCP performed post-ESWL, with complete clearance defined as clearance of >90% of the main pancreatic duct (MPD) stone volume, whereas partial clearance was defined as clearance of 50%–90% of the stone volume. Quality of life scores were assessed by the patient and ranged from 0 to 100, with higher scores indicating a better quality of life [22]. Physical and mental health were assessed according to the scores on the SF-36 questionnaire.

**Statistical analysis**

Depending on the distributional properties, outcome measures were expressed as the mean ± standard deviation (SD) or as median values with ranges. For normally distributed continuous data, statistical significance was assessed by the Student's t test; for categorical data, significance was assessed by the chi-squared test with Yates’ correction when appropriate or by the Fisher’s exact test; and for non-normally distributed continuous data, statistical significance was assessed by the Wilcoxon test. All reported P values are two-sided. A P value of <0.05 was established as the significance level. Missing follow-up data were considered to be missing at random.

**Results**

From March 2011 to March 2015, P-ESWL was performed in 1135 patients (72 in the pediatric group and 1063 in the control group).
Baseline characteristics

The demographic and clinical characteristics of the patients in the two groups differed significantly. Compared with the control group, the percentage of male subjects was lower in the pediatric group (56.9% vs. 72.8%; \( P = 0.004 \)). Regarding the etiology, more pediatric patients were classified as having idiopathic chronic pancreatitis (ICP; 95.8% vs. 69.4%; \( P < 0.001 \)). The pediatric group also had a lower prevalence of diabetes mellitus (5.6% vs. 29.8%; \( P < 0.001 \)) and steatorrhea (5.6% vs. 26.0%; \( P < 0.001 \)) (\( \rightarrow \) Table 2).

The age of the pediatric patients who underwent P-ESWL was 15.2 ± 2.2 years (range 8.0 – 18.0 years). Compared with the control group, the interval time from the diagnosis of pancreatic stones to P-ESWL being performed was shorter in the pediatric group (median 0.19 years vs. 0.5 years; \( P = 0.02 \)). Pediatric patients were subjected to fewer P-ESWL sessions (median 1.0 vs. 2.0; \( P < 0.001 \)) and fewer shocks (8265 ± 4918 vs. 11231 ± 7247; \( P < 0.001 \)) per person compared with the control group patients (\( \rightarrow \) Table 3).

Safety

No significant differences were observed between the pediatric and control groups regarding the overall and specific complications of P-ESWL (11.1% vs. 12.8%; \( P = 0.68 \)) (\( \rightarrow \) Table 4). In the pediatric group, eight complications of P-ESWL occurred in eight patients (8/72; 11.1%), with five of these patients presenting with mild post-ESWL pancreatitis (PEP), two presenting with moderate PEP, and one presenting with mild steinstrasse.

All of the patients were referred for ERCP. No significant differences were observed between the pediatric group (4/72; 5.6%) and control group (40/1063; 3.8%) in terms of post-ERCP complications (\( P = 0.36 \)).

Efficacy

During the ERCP performed post-ESWL, complete clearance of the stones was achieved in 86.1% of the patients in the pediatric group (62/72) and 94.4% in the matched controls (68/72; \( P = 0.07 \)) (\( \rightarrow \) Table 5).

The median follow-up period was 3.0 years (range 1.3 – 5.2 years) for the pediatric group and 2.8 years (1.4 – 5.0 years) for
the matched controls. Five patients in the pediatric group and 3/72 matched controls were lost to follow-up. Among the 67 patients (93.1%) receiving ongoing follow-up in the pediatric group, complete pain relief was achieved in 52 patients (52/67; 77.6%), and significant differences were not observed compared with the matched controls (55/69; 79.7%; \( P = 0.94 \)) (Table 6). Four pediatric patients and one matched control later underwent surgery because of poor outcomes after endoscopic therapy. One of the four underwent resection of a pancreatic pseudocyst combined with longitudinal pancreaticojejunostomy (LPJ) because of the enlarged pseudocyst; the other three patients underwent LPJ because of unrelieved pain. The one matched control who needed surgery underwent pancreatic tail resection plus splenectomy because of gastric variceal bleeding.

<table>
<thead>
<tr>
<th>Table 2 General characteristics of the pediatric group and the control group.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td>Mean age ± SD at onset of chronic pancreatitis, years</td>
</tr>
<tr>
<td>Mean age ± SD at diagnosis of chronic pancreatitis, years</td>
</tr>
<tr>
<td>Mean age ± SD at which stone(s) were identified, years</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
</tr>
<tr>
<td>Alcohol, n (%)</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
</tr>
<tr>
<td>Etiology, n (%)</td>
</tr>
<tr>
<td>• Alcoholic chronic pancreatitis</td>
</tr>
<tr>
<td>• Idiopathic chronic pancreatitis(^1)</td>
</tr>
<tr>
<td>• Others(^2)</td>
</tr>
<tr>
<td>Symptoms of chronic pancreatitis onset, n (%)</td>
</tr>
<tr>
<td>• Abdominal pain</td>
</tr>
<tr>
<td>• Diabetes mellitus/steatorrhea</td>
</tr>
<tr>
<td>• Others</td>
</tr>
<tr>
<td>Type of abdominal pain, n (%)</td>
</tr>
<tr>
<td>• Recurrent acute pancreatitis</td>
</tr>
<tr>
<td>• Recurrent abdominal pain without significantly increased serum amylase</td>
</tr>
<tr>
<td>• Recurrent acute pancreatitis and abdominal pain without significantly increased serum amylase</td>
</tr>
<tr>
<td>• Chronic pancreatic pain</td>
</tr>
<tr>
<td>Severe acute pancreatitis, n (%)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
</tr>
<tr>
<td>Steatorrhea, n (%)</td>
</tr>
<tr>
<td>Common bile duct stenosis, n (%)</td>
</tr>
<tr>
<td>Pancreatic pseudocyst, n (%)</td>
</tr>
<tr>
<td>Location of stone(s), n (%)</td>
</tr>
<tr>
<td>• Head</td>
</tr>
<tr>
<td>• Body/tail</td>
</tr>
<tr>
<td>• Head and at least another location</td>
</tr>
</tbody>
</table>

\(^1\) Whether pancreatic divisum and anomalous pancreaticobiliary junction are etiologies of chronic pancreatitis is disputable. Herein, these features are included under idiopathic chronic pancreatitis.

\(^2\) Includes hereditary chronic pancreatitis, pancreatic trauma, pancreatic anatomical abnormality, and hyperlipidemia. Among the pediatric patients, there was one case of hereditary chronic pancreatitis and two of pancreatic trauma. In the control group, there were 17 cases of hereditary pancreatitis, 24 of pancreatic anatomical abnormalities, two of pancreatic trauma, and two of hyperlipidemia.
In the pediatric group, the pain frequency \(P < 0.001\), VAS pain score \(P < 0.001\), and absences from school (median 40.0 days vs. 0.0 days; \(P < 0.001\)) decreased significantly, and the scores for quality of life (60.4± 20.7 vs. 83.7 ± 11.3; \(P < 0.001\)) and physical health based on the SF-36 (63.8 ±16.9 vs. 72.9 ± 15.1; \(P = 0.03\)) improved after the P-ESWL. No differences were observed in the mental health scores (68.0± 14.7 vs. 71.7 ± 11.1; \(P = 0.31\)) before and after P-ESWL. The weight, height, and body mass index (BMI) of the pediatric patients improved significantly at follow-up (▶Table 7).

The height of the boys in the pediatric group pre-ESWL was significantly lower compared with the standard heights for their ages \(P= 0.009\), and similar results were obtained for the girls \(P< 0.001\). At the end of follow-up, the heights of the boys resembled the standard heights for their ages \(P= 0.06\); however, similar effects were not noted for the girls \(P=0.02\) (▶Fig. 2).

### Discussion

P-ESWL has been successfully applied in the treatment of pancreatic stones since 1987 and is now recommended as the first-line therapy for adult patients with uncomplicated painful chronic pancreatitis and radiopaque stones ≥5 mm obstructing the MPD [11]. The safety and efficacy of P-ESWL have been
demonstrated in numerous studies; however, data for pediatric patients have not been previously reported [22–25]. In clinical studies of pediatric ERCP [8, 26], a proportion of the children were subjected to P-ESWL; however, the outcomes of the P-ESWL subgroup were not evaluated. Our study is the first to report that P-ESWL is a safe and effective treatment for pediatric patients with pancreatic stones. The risk of complications relating to P-ESWL was not increased in pediatric patients, and the efficacy of P-ESWL was demonstrated by the significant pain relief and effective stone clearance. The outcome was similar to the results of previous P-ESWL studies in adults [22, 23, 27, 28].

The etiology of chronic pancreatitis in pediatric patients is different from that in adults, with environmental factors, such as alcohol use and smoking, rarely affecting pediatric patients. In this study, 95.8% of patients in the pediatric group had ICP, and male patients were less predominant than in the control group. In fact, increasing evidence suggests that the contribution of genetic or hereditary causes has been underestimated and this may be responsible for a significant proportion of cases previously diagnosed as idiopathic [29].

Compared with the control group, the pediatric patients required fewer shock waves in their P-ESWL to achieve successful stone fragmentation. This result may be attributed to the reduced time from stone diagnosis to P-ESWL in the pediatric patients, which likely corresponded to the newly emerging stones having a softer texture and being of a smaller size. Another possible reason is that the distance between the skin and the stone is shorter in children. The shock waves are therefore absorbed less by the surrounding tissue and organs, reaching the stone with less loss of energy, so that the therapeutic effect of the shock waves is greater [30, 31].

The common complications of P-ESWL include PEP, bleeding, infection, steinstrasse, and perforation (Table 1) [11]. In this study, the same intensity of shock wave was applied in both adult and pediatric patients, and significant differences were not observed in the complication rate. In addition, anesthesia-related complications and arrhythmia were not observed in any of the pediatric patients. We conclude that this shock wave intensity and anesthesia method are safe for pediatric patients.

The long-term consequences of pancreatic inflammation and fibrosis in the natural disease course of chronic pancreatitis

<table>
<thead>
<tr>
<th>Table 6</th>
<th>Pain relief and further treatment at follow-up.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pediatric group (n=67)</td>
</tr>
<tr>
<td>Pain relief, n (%)</td>
<td></td>
</tr>
<tr>
<td>Complete¹</td>
<td>52 (77.6)</td>
</tr>
<tr>
<td>Partial²</td>
<td>8 (11.9)</td>
</tr>
<tr>
<td>No</td>
<td>7 (10.4)</td>
</tr>
<tr>
<td>Further ERCP(s)³, n (%)</td>
<td>20 (29.9)</td>
</tr>
<tr>
<td>Further surgery, n (%)</td>
<td>4 (6.0)</td>
</tr>
</tbody>
</table>

ERCP, endoscopic retrograde cholangiopancreatography.
¹ Izbicki pain score ≤10.
² Izbicki pain score >10 after a decrease of >50%.
³ Most ERCPs were performed for the replacement or withdrawal of pancreatic stents combined with clearance of the main pancreatic duct.

Fig. 2 The effect of having chronic pancreatitis and of pancreatic extracorporeal shock wave lithotripsy (P-ESWL) on growth in the pediatric group. All comparisons are made with standard heights for the same ages. a Heights of the children (n=67) before P-ESWL (P<0.001) and at the end of follow-up (P=0.005). b Heights of the boys (n=38) before P-ESWL (P=0.009) and at the end of follow-up (P=0.06). c Heights of the girls (n=29) before P-ESWL (P<0.001) and at the end of follow-up (P=0.02).
will invariably lead to exocrine pancreatic insufficiency (EPI) and diabetes. If EPI develops, children may develop steatorrhea, weight loss, and fat-soluble vitamin deficiencies (vitamins A, D, E, and K), and these changes retard the growth and development of children [5]. Our study revealed that the height of the boys pre-ESWL was significantly lower than the standard heights for their ages (\(P = 0.009\)), and similar results were noted for the girls (\(P < 0.001\)). These results indicate that chronic pancreatitis affects the growth of children. Pancreatic enzymes were prescribed for all of the pediatric patients according to the EPI guidelines [32, 33]. At follow-up, the height of the girls remained low compared with the standard heights for their ages (\(P = 0.02\)); however, significant differences were no longer detected in the boys (\(P = 0.06\)) (Fig. 2). This finding can be attributed to the fact that girls grow fastest from 9 to 11 years of age and achieve 95% of their final height by the age of 13 [34]. However, girls with chronic pancreatitis were heavily affected by the disease during the above period because the average age of onset for chronic pancreatitis was 9.9 ± 4.8 years and they did not receive P-ESWL until they were 15.2 ± 2.2 years old.

There are several limitations of our study. First, given the observational study design (cohort study), there is an inherent selection bias and the follow-up data for the entire control group were not acquired; however, we believe that the matched control comparison and the self-control comparison between pre-ESWL and post-ESWL provide persuasive evidence. Second, multiple confounders are present that can affect the growth of children in this age group and a longer length of follow-up is needed to better evaluate the prognosis of the children. Third, lack of genetic testing data prevents more intensive study of the disease. Fourth, the need for an ERCP post-ESWL is still controversial and this requires there to be a large-scale multicenter randomized controlled trial. Furthermore, a prospective study is necessary to compare the outcome of the P-ESWL strategy with pancreatic surgery, as several studies have reported satisfying results for pancreatic surgery in pediatric patients with chronic pancreatitis [13, 14, 35].

In conclusion, P-ESWL is a minimally invasive, safe, and effective procedure for the management of pediatric pancreatic stones. For these patients, P-ESWL can safely achieve signifi-
cant pain relief and stone clearance. Moreover, the therapy promotes growth and development in these pediatric patients, especially in the boys.

Competing interests

None

References

[34] Li H, Ji CY, Zong XN et al. [Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years]. Zhonghua Er Ke Za Zhi 2009; 47: 487 – 492